1. Genetic model could be the ideal new tool for testing Parkinson's disease therapies.

    "We believe we've found an approach that is most relevant to humans, in that our models of gene dysfunction mimic the etiology of Parkinson's disease rather than its pathology....

    News on Parkinsons

    Read more »
  2. New research findings about Huntington's disease

    This opens up new treatment strategies for diseases that involve impairment of the body's ability to break down...

    News from research

    Read more »
  3. New subtype of multiple sclerosis discovered

    The breakthrough provides a better understanding of the individualized nature of the disease says the research team. 

    MS new type

    Read more »
  4. Lower prices negotiated on 16 medicines

    Lower prices negotiated and provided as part of our ongoing mission to make medicines more accessible. 
    new prices 

    Read more »
  5. A new answer for treating migraines?

    7 need-to-knows about migraine as well as some updates on the latest treatment developments

    Blog post

    Read more »
  6. Image of the Year shows exceptional responses to cancer treatment

    Industry NewsThe dramatic before-and-after images show eight men's incredible response to cutting-edge treatment. 

    Read more »
  7. New immunotherapy shows reduction in tumor size for NSCLC patients

    Industry NewsIt’s believed that this immunotherapy and its dual approach to fighting cancer will be a notable complement to existing immuno-oncology treatments.

    Read more »
  8. Response to Keytruda (pembrolizumab) better in older patients, study suggests

    Industry NewsResearchers believe these differences are due to a reduced immunosuppressive tumor environment in older patients.

    Read more »
  9. T-cell therapy yields objective response rate of 52% in lymphoma (DLBCL) patients

    Industry NewsThe 52% (95% CI, 41-62) ORR included a complete response rate of 40% and a partial response rate of 12%.

    Read more »
  10. Keytruda-chemo combination shows beneficial response in treating metastatic NSCLC

    Industry NewsResearchers say the addition of Keytruda (pembrolizumab) in this study almost doubled the response rate of chemo for patients with NSCLC.

    Read more »
  11. New study suggests men and women may benefit differently from some immunotherapy medications

    News updateThe study showed that the relative survival gain almost doubled in men, compared to female patients, regardless of the type of cancer and drugs given.

    Read more »
  12. Efficacy issues with Keytruda and Tecentriq in some clinical trials

    The Food and Drug Administration (FDA) has drawn attention to efficacy issues associated with Keytruda or Tecentriq in some clinical trials - patients and healthcare professionals should take note.

    Industry news

    Read more »